Table 2.
Treatment sites and radiation details by patient
| Patient | First malignancy site | First RT total dose (Gy) | SMN or LR site | Re-RT total dose/fractionation (Gy) | Re-RT target | ESD of re-RT target volume (cm) | Interval between treatments (y) |
|---|---|---|---|---|---|---|---|
| 1 | Prostate | N/A | Prostate | 55/2.5 | Prostate, bilateral seminal vesicle | 7.6 | 11.25 |
| 2 | Lymphoma | N/A | Bladder | 30/1.5 twice daily | Pelvic and retroperitoneal lymph nodes | 8.6 | 32.0 |
| 3 | Prostate | 68-72 | Bladder | 64.8/1.8 | Bladder, prostate | 9.4 | 22.0 |
| 4 | Prostate | 63 | Prostate | 55/2.5 | Prostate, bladder, rectum | N/A | 21.0 |
| 5 | Bladder | 50.4 | Bladder | 59.6/1.8 | Periureteral tissues, urethra | 6.0 | 1.25 |
| 6 | Prostate | 63 | Bladder | 46/2.0 | Bladder | 16.3 | 19.0 |
| 7 | Prostate | 63 | Bladder | 28/7.0 | Bladder | 7.4 | 17.25 |
| 8 | Bladder | 66 | Bladder | 54.05/2.35 | Bladder | 6.4 | 1.92 |
| 9 | Bladder | 54 | Bladder | 50.4/1.8 | Pelvis | 13.1 | 0.6 |
| 10 | Prostate | 63 | Prostate | 30/2.5 | Pubic symphysis, bladder | N/A | 10.0 |
| 11 | Ureteral | 64 | Ureteral | 40.5/2.7 | Lower pelvis/groin mass | 4.7 | 0.2 |
| 12 | Prostate | 75.6 | Prostate | 50/2.5 | Penis to level of prostate | 8.5 | 4.3 |
| 13 | Prostate | 144 | Prostate | 55/2.5 | Prostate, bladder | 7.1 | 8.0 |
| 14 | Prostate | 75 | Bladder | 47.5/2.5 | Pelvic mass | 8.1 | 5.6 |
| 15 | Prostate | 75.6 | Prostate | 50/2.0 | Prostate | 7.9 | 4.3 |
| 16 | Prostate | N/A | Prostate | 37.5/2.5 | Pelvic mass | 8.8 | 10.0 |
| 17 | Prostate | 70.2 | Bladder | 50/2.5 | Bladder, right distal ureter, prostate | N/A | 11.0 |
| 18 | Prostate | 45+ brachytherapy boost to 155 | Bladder | 40.5/2.7 | Sacrum, bladder, prostate | 9.1 | 11.0 |
| 19 | Rectal | 55 | Bladder | 46/2.0 | Large bladder mass invading rectum | 13.1 | 22.0 |
| 20 | Ureteral | 65 | Bladder | 52.9/unknown | Bladder, right side wall pelvic mass | 8.9 | 2.2 |
| 21 | Prostate | 45+ brachytherapy boost to 155 | Bladder | 66/2.0 | Whole bladder | 8.7 | 6.0 |
| 22 | Prostate | 72 | Prostate | 50/2.5 | Pelvis | 10.3 | 6.0 |
| 23 | Prostate | 63 | Bladder | 50/2.5 | Bladder | 8.3 | 10.0 |
| 24 | Bladder | 54 | Bladder | 27.5/2.5 | Left pelvis, upper thigh | 12.5 | 0.75 |
| 25 | Prostate | 68 | Prostate | 35/2.5 | Sacrum, bladder | 6.2 | 9.0 |
| 26 | Penile | 30 | Penile | 55/2.5 | Penis, bilateral groin, left pelvic nodes | 12.6 | 1.0 |
| 27 | Prostate | 66.6 | Prostate | 64/2.0 | Bladder | 5.9 | 14.0 |
| 28 | Prostate | 66 | Bladder | 55/2.5 | Pelvic mass | 12.7 | 11.0 |
ESD, equivalent square diameter; LR, local recurrence; N/A, not available; re-RT, reirradiation; RT, radiation therapy; SMN, second malignant neoplasm.